Main > ONCOLOGY (**) > Skin Cancer>Melanoma>MET>BRAF+*** > Treatment > CH. N. Dabrafenib+Trametinib***



CH. N. Dabrafenib+Trametinib***'s subsections
(*) AU; CA; EU Approval
(*) USA Approval Date: 2015. 11.20
Companion Diagnostics>
Company
or BRAF+ Melanoma Involving Lymph
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 9
Patent>UpDate: 2018. 10.30.
TradeMark
TradeMark Web-Site

CH. N. Dabrafenib+Trametinib***'s products
This section has no products